Iperion

No quantified guidance, forward-work balance, or commercial revenue target is disclosed. The only forward commentary is qualitative: progressing certifications and moving toward commercial production and sales.

Using the calc pass's FY23 shape, HY23 represented 39.4% of FY23 revenue and 47.3% of FY23 EBITDA and NPAT – i.e. FY23 was second-half weighted on loss. Applied mechanically, HY24's NZ$462.6k loss at a similar shape would imply a full-year loss materially larger than FY23's NZ$280k, but the release does not support a more specific forecast. What the release does not support is any inference that the company is near commercial revenue, break-even cash flow, or funded beyond the near term.

• Funding plan. The filing does not disclose how operations will be funded beyond the NZ$441 cash balance – whether via placement, rights issue, debt, or related-party support.
• Commercialisation timeline and cost. Certifications and sales/marketing activity are referenced without dates, cost estimates, or an expected first-revenue period.
• Asset composition. Total assets of NZ$1.26m sit against cash of NZ$441, implying NZ$1.26m is held in non-cash assets whose nature, liquidity, and carrying basis are not detailed in the extraction.
• Liability profile. NZ$99.5k of liabilities is disclosed with no split between trade payables, accruals, related-party amounts, or any commitments.
• Share count and dilution risk. No share data is supplied, so the dilution implied by any near-term raise cannot be sized.

This briefing cannot assess solvency, probability or terms of any near-term capital raise, or the commercial viability of the product pivot – only the financial footprint already reported.